首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   8462篇
  免费   802篇
  国内免费   327篇
耳鼻咽喉   13篇
儿科学   22篇
妇产科学   199篇
基础医学   354篇
口腔科学   39篇
临床医学   259篇
内科学   344篇
皮肤病学   64篇
神经病学   276篇
特种医学   155篇
外科学   214篇
综合类   1442篇
预防医学   308篇
眼科学   24篇
药学   4522篇
  7篇
中国医学   1244篇
肿瘤学   105篇
  2023年   79篇
  2022年   146篇
  2021年   229篇
  2020年   247篇
  2019年   121篇
  2018年   145篇
  2017年   207篇
  2016年   304篇
  2015年   271篇
  2014年   749篇
  2013年   606篇
  2012年   779篇
  2011年   746篇
  2010年   580篇
  2009年   500篇
  2008年   541篇
  2007年   582篇
  2006年   436篇
  2005年   393篇
  2004年   297篇
  2003年   238篇
  2002年   190篇
  2001年   167篇
  2000年   150篇
  1999年   122篇
  1998年   73篇
  1997年   68篇
  1996年   55篇
  1995年   59篇
  1994年   55篇
  1993年   41篇
  1992年   37篇
  1991年   30篇
  1990年   35篇
  1989年   22篇
  1988年   37篇
  1987年   26篇
  1986年   32篇
  1985年   22篇
  1984年   17篇
  1983年   15篇
  1982年   23篇
  1981年   12篇
  1980年   25篇
  1979年   18篇
  1978年   17篇
  1977年   10篇
  1976年   13篇
  1975年   8篇
  1974年   5篇
排序方式: 共有9591条查询结果,搜索用时 31 毫秒
1.
目的:基于系统评价,比较水飞蓟宾胶囊与护肝片在改善脂肪肝相关生化指标方面的有效性和安全性。方法:计算机检索万方数据库、中国生物医学文献数据库、中国知网、the Cochrane Library、Embase和PubMed等数据库,纳入水飞蓟宾胶囊与护肝片治疗脂肪肝的随机对照试验(研究组的治疗方案为水飞蓟宾胶囊,对照组为护肝片),检索时间为建库至2021年10月。提取资料、选取文献并评价纳入文献的偏倚风险后,采用RevMan 5.4软件进行Meta分析。结果:共纳入9篇文献,包括700例患者(研究组患者384例,对照组患者316例)。Meta分析结果显示,研究组患者的总有效率(OR=4.39,95%CI=2.95~6.55,P<0.00001)、显效率(OR=2.27,95%CI=1.56~3.32,P<0.0001)、治愈率(OR=2.67,95%CI=1.67~4.28,P<0.0001)、丙氨酸转氨酶水平(MD=-12.16,95%CI=-15.06~-9.26,P<0.00001)、天冬氨酸转氨酶水平(MD=-12.32,95%CI=-15.26~-9.39,P<0.00001)、三酰甘油水平(MD=-0.46,95%CI=-0.69~-0.22,P<0.0001)和总胆固醇水平(MD=-1.27,95%CI=-2.17~-0.37,P=0.006)均显著优于对照组,差异均有统计学意义;研究组患者的不良反应发生率较对照组显著降低,差异有统计学意义(OR=0.26,95%CI=0.09~0.78,P=0.02)。结论:现有证据表明,相比于护肝片,水飞蓟宾胶囊在改善脂肪肝相关生化指标方面更有效,安全性更高。因选取的文献数量和文献质量的限制,上述结论有待今后更多高质量的随机对照试验予以验证。  相似文献   
2.
林笑晗  贲腾  田尧  马林 《转化医学杂志》2022,11(4):233-236+217
目的 探究复方蛋氨酸胆碱结合苦黄注射液在酒精性脂肪肝治疗中的疗效及对肝纤维化的影响。方法 按照随机数字表法将2019年1月至2021年12月海安市人民医院收治并确诊的104例酒精性脂肪肝患者分为对照组和观察组,各52例。对照组给予复方蛋氨酸胆碱治疗,观察组苦黄注射液联合复方蛋氨酸胆碱治疗。两组患者均连续治疗1个月。采用全自动生化分析仪检测两组患者治疗前后血清丙氨酸转移酶(alanine transferase,ALT)、天冬氨酸转氨酶(aspartate aminotransferase,AST)、总胆固醇(total cholesterol ,TC)、三酰甘油(triacylglycerol,TG)、总胆红素(total bilirubin,TBil)水平;采用放射免疫法检测两组患者治疗前后血清层粘连蛋白(laminin,LN)、透明质酸(hyaluronic acid,HA)、Ⅲ型前胶原N端肽(type III procollagen N-terminal peptide,PC Ⅲ)及Ⅳ型胶原(type IV collagen,Ⅳ-C)水平。比较两组患者的临床症状改善情况、临床疗效、肝功能指标及肝纤维化指标。结果 观察组治疗后的腹胀、肝区不适、黄疸、痞满等症状消失时间分别为(3.9±0.1) d、(9.8±0.2) d、(11.5±0.7)d、(3.8±0.2) d,均短于对照组分别为(7.5±0.3) d、(14.3±0.4) d、(15.6±0.8) d、(7.4±0.3) d(均P<0.05)。观察组临床总有效率高于对照组(94.2% vs 78.9%)(χ2=5.283,P=0.022)。观察组ALT、AST、TC、TG、TBil水平分别为(31.5±5.3) IU/L、(36.4±3.4) IU/L、(4.1±0.2) mmol/L、(1.4±0.3) mmol/L、(12.6±3.1) μmol/L,低于对照组[分别为(57.4±5.6) IU/L、(54.7±3.5) IU/L、(6.4±0.4) mmol/L、(2.6±0.5) mmol/L、(21.2±5.3) μmol/L](均P<0.05)。观察组治疗后LN、HA、PC Ⅲ、Ⅳ-C水平分别为(51.6±9.4) μg/L、(32.5±7.4) μg/L、(7.5±1.8) ng/mL、(32.3±4.2) μg/L,均低于对照组[分别为(80.5±10.3) μg/L、(58.7±12.2) μg/L、(16.5±3.6) ng/mL、(71.2±8.6) μg/L](均P<0.05)。对照组和观察组不良反应发生率分别为7.68%、3.84%,两组比较无明显差异(χ2=0.707,P=0.400)。结论 复方蛋氨酸胆碱结合苦黄注射液在酒精性脂肪肝患者中的治疗疗效显著,可改善患者的临床症状和肝功能,延缓肝纤维化的进程,安全性高。  相似文献   
3.
ObjectiveTo assess the efficacy of Da Chaihu decoction combined with metformin tablets on patients with type 2 diabetes compared with metformin alone.MethodsThis systematic review and meta‐analysis is written based on 2020 PRISMA Extension for Chinese Herbal Medicines 2020 (PRISMA-CHM 2020) reporting guidelines. We reviewed all the relevant studies from a search of the following databases from inception to February 2022 without any language restriction: Excerpta Medica Database (EMBASE), Google Scholar, PubMed, Cochrane Library, China National Knowledge Infrastructure (CNKI), VIP Information, Wanfang Data, and the Chinese Biomedical Literature Database(CBM). Data were extracted and the quality was independently evaluated by two reviewers, based on the inclusion and exclusion criteria. Data were analyzed using the Cochrane software RevMan 5.3.ResultsSix randomized controlled trials comprising 516 participants were included.The meta‐analysis revealed the Da Chaihu decoction combined with metformin tablets group was significantly superior to the metformin tablets group in terms of fasting blood glucose(FPG) (−0.66 mmol/L; 95 % CI (confidence intervals) [− 1.28, − 0.04]), plasma glucose 2 h after meal (2-h PG) (−1.18 mmol/L; 95 % CI [−1.94, −0.42]) in six RCTs, body mass index (BMI) (−3.07 mmol/L; 95 % CI [−6.89, 0.75]) in three RCTs, glycosylated hemoglobin (HbAlc) (−0.36 mmol/L; 95 % CI [−1.04, 0.31]) in three RCTs, and triglycerides (TG) (−0.76 mmol/L; 95 % CI [−1.37, −0.15]) in two RCTs. In two RCTs, there were significant differences in terms of total cholesterol (TC) (−0.97 mmol/L; 95 % CI [−1.18, −0.76]).ConclusionsVery low-quality research shows that Da Chaihu decoction combined with metformin tablets exert a certain level of efficacy on patients with type 2 diabetes compared with metformin alone. However, random sequence generation methodology was reported in five studies leading to the low quality of the included studies. None of the six studies depicted the blinding method, allocation concealment, selective reporting, and assessed the purity and potency of the product. This observation requires verification through high-quality, multi-center, double-blinded randomized controlled trials, and assesses the purity and potency of the product.  相似文献   
4.
目的制备盐酸益母草碱片,并进行质量评价。方法采用湿法制粒技术,以盐酸益母草碱为原料药,采用单因素实验筛选填充剂、崩解剂、黏合剂、润滑剂种类;结合正交实验,以15 min累积溶出度(以水为溶出介质)为指标,筛选崩解剂占比、黏合剂溶液质量分数、润滑剂占比,并进行验证。按2020年版《中国药典》(四部)通则方法对所制盐酸益母草碱片的体外溶出行为(溶出介质分别为pH1.2的盐酸溶液、pH4.5的醋酸-醋酸钠溶液、pH6.8的磷酸盐缓冲液、水)、片剂外观、硬度、脆碎度、含量均匀度进行检测。结果盐酸益母草碱片的最优处方为盐酸益母草碱原料药500 mg、糊精9250 mg、交联聚维酮200 mg、硬脂酸镁50 mg、1%羟丙甲纤维素溶液4 mL。所制3批片剂的平均15 min累积溶出度为81.25%(RSD=1.12%,n=3)。在上述4种溶出介质中,所制片剂均能在30 min内达到溶出平衡,且累积溶出度均超过85%。所制片剂外观颜色均一,呈米黄色,表面光滑,边缘完整,无杂色、斑点、异物等,硬度为57.3 N(n=6),减重率为0.15%,含量均匀度符合2020年版《中国药典》(四部)相关规定。结论成功制备了盐酸益母草碱片,且质量符合相关规定。  相似文献   
5.
Background and aimsMenopause may reduce fat oxidation. We investigated whether sex hormone profile explains resting fat oxidation (RFO) or peak fat oxidation (PFO) during incremental cycling in middle-aged women. Secondarily, we studied associations of RFO and PFO with glucose regulation.Method and resultsWe measured RFO and PFO of 42 women (age 52–58 years) with indirect calorimetry. Seven participants were pre- or perimenopausal, 26 were postmenopausal, and nine were postmenopausal hormone therapy users. Serum estradiol (E2), follicle-stimulating hormone, progesterone, and testosterone levels were quantified with immunoassays. Insulin sensitivity (Matsuda index) and glucose tolerance (area under the curve) were determined by glucose tolerance testing. Body composition was assessed with dual-energy X-ray absorptiometry; physical activity with self-report and accelerometry; and diet, with food diaries. Menopausal status or sex hormone levels were not associated with the fat oxidation outcomes. RFO determinants were fat mass (β = 0.44, P = 0.006) and preceding energy intake (β = ?0.40, P = 0.019). Cardiorespiratory fitness (β = 0.59, P = 0.002), lean mass (β = 0.49, P = 0.002) and physical activity (self-reported β = 0.37, P = 0.020; accelerometer-measured β = 0.35, P = 0.024) explained PFO. RFO and PFO were not related to insulin sensitivity. Higher RFO was associated with poorer glucose tolerance (β = 0.52, P = 0.002).ConclusionAmong studied middle-aged women, sex hormone profile did not explain RFO or PFO, and higher fat oxidation capacity did not indicate better glucose control.  相似文献   
6.
《Saudi Pharmaceutical Journal》2022,30(11):1589-1602
PurposeThe aim of this study was to design fast dissolving tablets (FDT) of the anti –psychiatric drug haloperidol in solid dispersion forms as a way to enhance its dissolution profile and anti-psychiatric effect.MethodsSolubility studies of haloperidol in various polymers solutions were investigated. The selected polymer with high drug solubility (Poly ethylene glycol 4000) was used for preparation of solid dispersion through two methods solvent evaporation method and melting method. Haloperidol solid dispersion mixed with other solid powder excipients and compressed into tablets. The resulted tablets were evaluated according to British Pharmacopoeia (B.P.) specifications. Pre- and post -compression studies were performed to determine the flow properties and evaluate the solid dispersion systems, followed by in vivo studies through forced swimming test (FST)ResultsPre-compression studies showed adequate flowability and compatibility of polymer and solid excipients with haloperidol. The selected solid dispersion tablet (SD2) demonstrated the best disintegration and water absorption ratio in addition to satisfactory friability and hardness. Attempts of in vitro dissolution results and thermodynamic stability studies showed acceptable results for (SD2) formulation containing PEG 4000 polymer prepared by melting method.The in vivo study of (SD2) formulation revealed the highest immobility time to rats compared to control rats and others treated with commercial haloperidol product.ConclusionFast dissolving tablets prepared from solid dispersion of haloperidol with PEG4000 expressed rapid onset of action with enhanced anti-psychiatric effect of haloperidol.  相似文献   
7.
《Annales d'endocrinologie》2022,83(4):244-249
Turner syndrome (TS) is tightly associated with hypergonadotropic hypogonadism and ovarian dysgenesis, typically resulting in infertility in the great majority of patients. Therefore females with TS are usually treated with female sex steroids from 11–12 years of age until the normal age of natural menopause of around 53–54 years of age. Infertility is rated among females with TS as a distressing concern and a detractor from a good quality of life. Options for motherhood for females with TS has expanded during recent years. Originally, only adoption was an option, unless of course for the small minority of TS females that still has ovarian function and are capable of achieving pregnancy through normal means. Oocyte donation has become the mainstream option in many countries and seems to work well, especially if patients have been treated with optimal estrogen and gestagen for a prolonged time before the intervention. It comes with an increased risk of cardiovascular complications and TS oocyte donation pregnancies are viewed as high risk pregnancies necessitating increased vigilance. Oocyte cryopreservation of own oocytes is also becoming an option in a select group of TS and has special challenges. Ovarian tissue cryopreservation is a promising new techniques that has been applied successfully in children with cancer. Currently, several trials are running around the world evaluating this techniques in TS. The genetics and genomics behind the ovarian dysgenesis seen in TS is not understood, but new studies have elucidated global changes in DNA methylation and RNA expression in blood from persons with TS and it is likely that similar changes are present in the ovaries. We still, however, need more thorough research to fully uncover the genetic background of ovarian failure in TS. Gene expression studies and methylation analysis from ovarian TS tissues still needs to be performed.  相似文献   
8.
杨小波  利益  郭碧林 《世界中医药》2020,15(8):1171-1174
目的:探究肾炎方联合缬沙坦分散片治疗慢性肾小球肾炎患者的疗效及对肾功能的影响。方法:选取2016年2月至2019年2月重庆医科大学附属一医院合川医院肾脏内科收治的慢性肾小球肾炎患者122例作为研究对象,随机分为对照组和观察组,每组61例。对照组患者采用下缬沙坦分散片治疗,观察组在对照组基础上采用自拟肾炎方与缬沙坦分散片联合治疗,分析比较2组患者的肾功能指标的动态变化、炎性因子的表达水平、临床疗效及治疗后不良反应。结果:治疗后观察组TC、TG、BUN、Scr及24 hUPE5项指标的动态变化均低于对照组,差异有统计学意义(P<0.05),且观察组ALB动态变化高于对照组,差异有统计学意义(P<0.05);治疗后观察组IL-6、IL-10、CRP及TNF-α水平明显低于对照组,差异有统计学意义(P<0.05),观察组治疗有效率(98.4%)优于对照组(86.9%),差异有统计学意义(P<0.05);观察组不良反应发生率(6.6%)低于对照组(31.1%),差异有统计学意义(P<0.05)。结论:采用自拟肾炎方与缬沙坦分散片联合的治疗方案可增强疗效,提升肾功能,降低促炎性因子的表达水平及不良反应,值得在临床中推广普及。  相似文献   
9.
目的分析冠状动脉粥样硬化性心脏病(冠心病)心肌梗死后合并焦虑症状患者采用氟哌噻吨美利曲辛片(商品名:黛力新)治疗的临床效果。方法80例冠心病心肌梗死后合并焦虑症状患者,采用随机数字表法分为对照组与干预组,每组40例。对照组开展规范化常规治疗,干预组在对照组基础上给予黛力新治疗。比较治疗前后两组患者的心率与血压水平、焦虑自评量表(SAS)评分,并进行临床疗效评价。结果治疗4周后,干预组的心率、收缩压、舒张压分别为(88.5±7.2)次/min、(133.5±6.2)mm Hg(1 mm Hg=0.133 kPa)、(90.1±5.9)mm Hg,对照组分别为(92.5±7.8)次/min、(142.0±6.4)mm Hg、(95.8±6.6)mm Hg;治疗12周后,干预组的心率、收缩压、舒张压分别为(84.2±6.7)次/min、(128.2±7.3)mm Hg、(82.4±6.3)mm Hg,对照组分别为(88.0±7.5)次/min、(138.0±8.9)mm Hg、(90.5±7.0)mm Hg,治疗4周后和治疗12周后,两组的心率、收缩压、舒张压均较治疗前降低,且干预组降低幅度大于对照组,差异有统计学意义(P<0.05)。治疗4周后,干预组的SAS评分为(51.27±5.52)分,对照组为(55.32±6.37)分,治疗12周后,干预组的SAS评分为(39.56±5.96)分,对照组为(50.31±8.79)分。治疗4周后和治疗12周后,两组的SAS评分均较治疗前降低,且干预组降低幅度大于对照组,差异有统计学意义(P<0.05)。干预组的治疗总有效率90.00%高于对照组的67.50%,差异有统计学意义(P<0.05)。结论基于规范化常规治疗,对冠心病心肌梗死后合并焦虑症状患者进行黛力新治疗,有助于焦虑症状明显改善,有利于稳定血压和心率,促进病情恢复。  相似文献   
10.
目的分析讨论贝伐珠单抗注射液联合盐酸埃克替尼片治疗中晚期非小细胞肺癌的临床疗效及安全性。方法选择某院治疗的72例中晚期非小细胞肺癌患者(2017年12月~2018年12月)展开研究,以随机法将患者均分为观察组与参照组,各有36例。参照组接受盐酸埃克替尼片治疗,观察组接受贝伐珠单抗注射液联合盐酸埃克替尼片治疗。结果观察组总缓解率高于参照组(P<0.05);两组患者治疗前的血清肿瘤标志物水平比较无统计学意义;经治疗,观察组VEGF(血管内皮生长因子)、CA125(糖类抗原125)以及CYFRA21-1(细胞角质白19片段)等血清肿瘤标志物水平均低于对照组(P<0.05);观察组血小板减少、白细胞降低、蛋白尿、胃肠道反应等毒副反应发生率均低于参照组(P<0.05)。结论对中晚期非小细胞肺癌采取贝伐珠单抗注射液联合盐酸埃克替尼片治疗,可有效降低血清肿瘤标志物水平以及毒副反应,疗效显著。  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号